WT1 mRNA in peripheral blood enables early prognostic stratification in AML patients receiving venetoclax and azacitidine therapy
Hiroyuki Sugiura(Okayama University), Yoshinobu Maeda(Okayama University), Kazutaka Sunami(National Hospital Organization), Masanori Makita(Okayama Prefecture), Tomohiro Urata(Okayama University Hospital), Tomofumi Yano(Okayama Rosai Hospital), T Ishikawa(Okayama University Hospital), Kyosuke Saeki(Ehime Prefectural Central Hospital), Takeru Asano(Okayama University), Toshi Imai, Takanori Yoshioka(Okayama Medical Center), Yuichiro Nawa(Ehime Prefectural Central Hospital), Yasushi Hiramatsu(Himeji Red Cross Hospital), Maiko Kimura(Okayama Red Cross General Hospital), Shoji Asakura(Okayama Rosai Hospital), Makoto Takeuchi(Okayama Red Cross General Hospital), Kazuhiko Yamamoto(Okayama Prefecture), Noboru Asada(Okayama University), Makoto Nakamura(Okayama Prefecture), Masaya Abe(Okayama University Hospital)
Cited by 0
Related Papers
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|386
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11
|Blood Advances|2020|127
LKB1-Mediated Spatial Control of GSK3 and Adenomatous Polyposis Coli Contributes to Centrosomal Forward Movement and Neuronal Migration in the Developing Neocortex
|Journal of Neuroscience|2010|62
Spectroscopic evidence of the formation of (V,Ti)O2 solid solution in VO2 thinner films grown on TiO2(001) substrates
|Journal of Applied Physics|2011|30